Low-dose naltrexone: A possible safe effective treatment for autoimmune disease and cancer (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Low-dose naltrexone: A possible safe effective treatment for autoimmune disease and cancer

Anti-Aging Therapeutics, Volume 12, Chapter 3
January 2009
https://books.google.co.il/books?id=BSfzEE0tT9cC&lpg=PR7&dq=low%20dose%20naltrexone&pg=PR7#v=onepage&q=low%20dose%20naltrexone&f=false

Naltrexone is an opiate antagonist drug that has been used safely for 25 years in addiction medicine. Research has shown that in addition to its opiate antagonist properties at 50-300 mg per day dosages, it has immunoregulatory properties at dosages as low as 3.0 mg, Low dose naltrexone (LDN) improves the clinical state of patients with autoimmune diseases such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis. Another impressive property of LDN is its ability to arrest cancer cell growth. The remarkable fact is LDN can enhance the immune system for these two major disease classifications with little or no side effects. This paper will describe the science behind LDNs physiological mechanisms to reduce the effects of autoimmune disease and inhibit cancer cell growth. The author hopes to generate research interest in these mechanisms of disease modification, which enhance the body's own immune system without side effects.